Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

In Vivo Functional Platform Targeting Patient-Derived Xenografts Identifies WDR5-Myc Association as a Critical Determinant of Pancreatic Cancer
Alessandro Carugo, Giannicola Genovese, Sahil Seth, et al.
Cell Reports (2016) Vol. 16, Iss. 1, pp. 133-147
Open Access | Times Cited: 125

Showing 1-25 of 125 citing articles:

Interrogating open issues in cancer precision medicine with patient-derived xenografts
Annette T. Byrne, Denis Alférez, Frédéric Amant, et al.
Nature reviews. Cancer (2017) Vol. 17, Iss. 4, pp. 254-268
Open Access | Times Cited: 600
Increased Tumor Glycolysis Characterizes Immune Resistance to Adoptive T Cell Therapy
Tina Cascone, Jodi A. McKenzie, Rina M. Mbofung, et al.
Cell Metabolism (2018) Vol. 27, Iss. 5, pp. 977-987.e4
Open Access | Times Cited: 504
Accurate and efficient detection of gene fusions from RNA sequencing data
Sebastian Uhrig, Julia Ellermann, Tatjana Walther, et al.
Genome Research (2021) Vol. 31, Iss. 3, pp. 448-460
Open Access | Times Cited: 330
MYC protein interactors in gene transcription and cancer
Corey Lourenco, Diana Resetca, Cornelia Redel, et al.
Nature reviews. Cancer (2021) Vol. 21, Iss. 9, pp. 579-591
Closed Access | Times Cited: 246
Syndecan 1 is a critical mediator of macropinocytosis in pancreatic cancer
Wantong Yao, Johnathon L. Rose, Wei Wang, et al.
Nature (2019) Vol. 568, Iss. 7752, pp. 410-414
Open Access | Times Cited: 164
A selective WDR5 degrader inhibits acute myeloid leukemia in patient-derived mouse models
Xufen Yu, Dongxu Li, Jithesh Kottur, et al.
Science Translational Medicine (2021) Vol. 13, Iss. 613
Open Access | Times Cited: 118
KRASG12D inhibition reprograms the microenvironment of early and advanced pancreatic cancer to promote FAS-mediated killing by CD8+ T cells
Krishnan K. Mahadevan, Kathleen M. McAndrews, Valerie S. LeBleu, et al.
Cancer Cell (2023) Vol. 41, Iss. 9, pp. 1606-1620.e8
Open Access | Times Cited: 102
Mechanisms of Resistance to Oncogenic KRAS Inhibition in Pancreatic Cancer
Julien Dilly, Megan T. Hoffman, Laleh Abbassi, et al.
Cancer Discovery (2024) Vol. 14, Iss. 11, pp. 2135-2161
Closed Access | Times Cited: 41
Brd7 loss reawakens dormant metastasis initiating cells in lung by forging an immunosuppressive niche
Jayanta Mondal, Junfeng Zhang, Qing Feng, et al.
Nature Communications (2025) Vol. 16, Iss. 1
Open Access | Times Cited: 2
MYC—Master Regulator of the Cancer Epigenome and Transcriptome
Candace J. Poole, Jan van Riggelen
Genes (2017) Vol. 8, Iss. 5, pp. 142-142
Open Access | Times Cited: 168
Moonlighting with WDR5: A Cellular Multitasker
Alissa D. Guarnaccia, William P. Tansey
Journal of Clinical Medicine (2018) Vol. 7, Iss. 2, pp. 21-21
Open Access | Times Cited: 128
Synthetic vulnerabilities of mesenchymal subpopulations in pancreatic cancer
Giannicola Genovese, Alessandro Carugo, James M. Tepper, et al.
Nature (2017) Vol. 542, Iss. 7641, pp. 362-366
Open Access | Times Cited: 117
The role of histone methylation in the development of digestive cancers: a potential direction for cancer management
Yuan Chen, Bo Ren, Jinshou Yang, et al.
Signal Transduction and Targeted Therapy (2020) Vol. 5, Iss. 1
Open Access | Times Cited: 105
Displacement of WDR5 from Chromatin by a WIN Site Inhibitor with Picomolar Affinity
Erin R. Aho, Jing Wang, Rocco D. Gogliotti, et al.
Cell Reports (2019) Vol. 26, Iss. 11, pp. 2916-2928.e13
Open Access | Times Cited: 99
Interaction of the oncoprotein transcription factor MYC with its chromatin cofactor WDR5 is essential for tumor maintenance
Lance R. Thomas, Clare M. Adams, Jing Wang, et al.
Proceedings of the National Academy of Sciences (2019) Vol. 116, Iss. 50, pp. 25260-25268
Open Access | Times Cited: 96
ZEB1/NuRD complex suppresses TBC1D2b to stimulate E-cadherin internalization and promote metastasis in lung cancer
Roxsan Manshouri, Étienne Coyaud, Samrat T. Kundu, et al.
Nature Communications (2019) Vol. 10, Iss. 1
Open Access | Times Cited: 88
Pre-existing Functional Heterogeneity of Tumorigenic Compartment as the Origin of Chemoresistance in Pancreatic Tumors
Sahil Seth, Chieh-Yuan Li, I-Lin Ho, et al.
Cell Reports (2019) Vol. 26, Iss. 6, pp. 1518-1532.e9
Open Access | Times Cited: 83
Dietary glutamine supplementation suppresses epigenetically-activated oncogenic pathways to inhibit melanoma tumour growth
Mari B. Ishak Gabra, Ying Yang, Haiqing Li, et al.
Nature Communications (2020) Vol. 11, Iss. 1
Open Access | Times Cited: 77
Design, Synthesis, and Evaluation of WD-Repeat-Containing Protein 5 (WDR5) Degraders
Anja Dölle, Bikash Adhikari, Andreas Krämer, et al.
Journal of Medicinal Chemistry (2021) Vol. 64, Iss. 15, pp. 10682-10710
Open Access | Times Cited: 64
WDR5 facilitates EMT and metastasis of CCA by increasing HIF-1α accumulation in Myc-dependent and independent pathways
Tianli Chen, Kangshuai Li, Zengli Liu, et al.
Molecular Therapy (2021) Vol. 29, Iss. 6, pp. 2134-2150
Open Access | Times Cited: 58
Targeting WD repeat domain 5 enhances chemosensitivity and inhibits proliferation and programmed death-ligand 1 expression in bladder cancer
Jingtong Zhang, Qianghua Zhou, Keji Xie, et al.
Journal of Experimental & Clinical Cancer Research (2021) Vol. 40, Iss. 1
Open Access | Times Cited: 58
Discovery of a dual WDR5 and Ikaros PROTAC degrader as an anti-cancer therapeutic
Dongxu Li, Xufen Yu, Jithesh Kottur, et al.
Oncogene (2022) Vol. 41, Iss. 24, pp. 3328-3340
Open Access | Times Cited: 40
MYC the oncogene from hell: Novel opportunities for cancer therapy
Adriana Papadimitropoulou, Maria Makri, Grigoris Zoidis
European Journal of Medicinal Chemistry (2024) Vol. 267, pp. 116194-116194
Closed Access | Times Cited: 11
Differentiation therapy and the mechanisms that terminate cancer cell proliferation without harming normal cells
Francis Enane, Yogen Saunthararajah, Murray Korc
Cell Death and Disease (2018) Vol. 9, Iss. 9
Open Access | Times Cited: 80
Synthetic Lethal Vulnerabilities in KRAS-Mutant Cancers
Andrew J. Aguirre, William C. Hahn
Cold Spring Harbor Perspectives in Medicine (2017) Vol. 8, Iss. 8, pp. a031518-a031518
Open Access | Times Cited: 73
Page 1 - Next Page

Scroll to top